{"pmid":32427361,"title":"4 Cases: HIV and SARS-CoV-2 Co-infection in patients from Long Island, New York.","text":["4 Cases: HIV and SARS-CoV-2 Co-infection in patients from Long Island, New York.","Originating from Wuhan, China, the novel coronavirus 2019 (SARS-CoV-2) has been spreading worldwide since the end of 2019. The most common features of these patients include fever, cough, myalgia or fatigue [1]. As of April 16, 2020 the CDC has reported 605,390 cases and 24,582 deaths in the United States. The illness continues to spread through the world infecting people with various different comorbid conditions. Presented here are four cases which represent some of the first cases of HIV and SARS-CoV-2 coinfection in Long Island, New York. These HIV infected patients were compliant with their HIV medication regimen and had robust CD4 T cell counts. The clinical severity ranged from mild to requiring hospitalization. Three of the four patients had fever and two had cough. One patient presented with diarrhea, the incidence rate of diarrhea in SARS-CoV-2 infection range from 2% to 50% of cases [4]. One patient had anosmia and aguesia, in a study by Moein et al, the 98% of SARS-CoV-2 infected patient experienced some smell dysfunction [5]. One patient required hospitalization however this patient was also infected with influenza A. These cases suggest that uncomplicated cases of SARS-CoV-2 in an HIV infected patient can be managed with self-isolation at home. This article is protected by copyright. All rights reserved.","J Med Virol","Benkovic, Scott","Kim, Michelle","Sin, Eric","32427361"],"abstract":["Originating from Wuhan, China, the novel coronavirus 2019 (SARS-CoV-2) has been spreading worldwide since the end of 2019. The most common features of these patients include fever, cough, myalgia or fatigue [1]. As of April 16, 2020 the CDC has reported 605,390 cases and 24,582 deaths in the United States. The illness continues to spread through the world infecting people with various different comorbid conditions. Presented here are four cases which represent some of the first cases of HIV and SARS-CoV-2 coinfection in Long Island, New York. These HIV infected patients were compliant with their HIV medication regimen and had robust CD4 T cell counts. The clinical severity ranged from mild to requiring hospitalization. Three of the four patients had fever and two had cough. One patient presented with diarrhea, the incidence rate of diarrhea in SARS-CoV-2 infection range from 2% to 50% of cases [4]. One patient had anosmia and aguesia, in a study by Moein et al, the 98% of SARS-CoV-2 infected patient experienced some smell dysfunction [5]. One patient required hospitalization however this patient was also infected with influenza A. These cases suggest that uncomplicated cases of SARS-CoV-2 in an HIV infected patient can be managed with self-isolation at home. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Benkovic, Scott","Kim, Michelle","Sin, Eric"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427361","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26029","keywords":["coronavirus","human immunodeficiency virus","influenza virus","pandemics"],"locations":["Wuhan","China","myalgia","fatigue","United States","Long Island","New York","Long Island","New York"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1667352728870846466,"score":9.490897,"similar":[{"pmid":32469614,"title":"A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.","text":["A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.","The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm(3) and suppressed HIV viral loads at the time of COVID-19 diagnosis. All five patients were hospitalized, two required supplemental oxygen, and none required mechanical ventilation. Four patients were treated with azithromycin and a cephalosporin and two were also treated with hydroxychloroquine. The median length of stay was 3 days (range 2-7). All patients recovered. More research is needed to understand the risks of COVID-19 among PLWH and the impact of ART on outcomes for patients with COVID-19.","AIDS Patient Care STDS","Ridgway, Jessica P","Farley, Brianna","Benoit, Jean-Luc","Frohne, Christopher","Hazra, Aniruddha","Pettit, Natasha","Pho, Mai","Pursell, Kenneth","Saltzman, Jina","Schmitt, Jessica","Uvin, Arno Ziggy","Pitrak, David","McNulty, Moira","32469614"],"abstract":["The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm(3) and suppressed HIV viral loads at the time of COVID-19 diagnosis. All five patients were hospitalized, two required supplemental oxygen, and none required mechanical ventilation. Four patients were treated with azithromycin and a cephalosporin and two were also treated with hydroxychloroquine. The median length of stay was 3 days (range 2-7). All patients recovered. More research is needed to understand the risks of COVID-19 among PLWH and the impact of ART on outcomes for patients with COVID-19."],"journal":"AIDS Patient Care STDS","authors":["Ridgway, Jessica P","Farley, Brianna","Benoit, Jean-Luc","Frohne, Christopher","Hazra, Aniruddha","Pettit, Natasha","Pho, Mai","Pursell, Kenneth","Saltzman, Jina","Schmitt, Jessica","Uvin, Arno Ziggy","Pitrak, David","McNulty, Moira"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469614","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1089/apc.2020.0103","keywords":["covid-19","hiv","coinfection"],"locations":["African American","Chicago","Illinois"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668167109881888768,"score":257.38638},{"pmid":32437000,"title":"HIV and SARS-CoV-2 co-infection: A case report from Uganda.","text":["HIV and SARS-CoV-2 co-infection: A case report from Uganda.","There are no reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HIV co-infection from sub-Saharan Africa where 70% of people living with HIV are found. We report a case of HIV/SARS-CoV-2 co-infection from Uganda. A 34 year old HIV-positive female on antiretroviral therapy (tenofovir disoproxil fumarate, lamivudine and efavirenz) for 5 years, tested positive for SARS-CoV-2, the causative agent for coronavirus disease 19 (COVID-19). She was asymptomatic at presentation but subsequently developed headache, chest pain, diarrhoea, anorexia and fatigue on day 3 of isolation without cough, fever or shortness of breath. Her CD4 count was 965 cells/mm(3) , the HIV viral load was undetectable (<1,000 cells/mm(3) ) and other laboratory work up was normal. She was successfully managed with hydroxychloroquine and broad spectrum antibiotics, and was discharged after 24 days. This case demonstrates an atypical clinical presentation of COVID - 19 in an HIV infected patient without other co-morbidity. This article is protected by copyright. All rights reserved.","J Med Virol","Baluku, Joseph Baruch","Mwebaza, Shem","Ingabire, Gloria","Nsereko, Chris","Muwanga, Moses","32437000"],"abstract":["There are no reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and HIV co-infection from sub-Saharan Africa where 70% of people living with HIV are found. We report a case of HIV/SARS-CoV-2 co-infection from Uganda. A 34 year old HIV-positive female on antiretroviral therapy (tenofovir disoproxil fumarate, lamivudine and efavirenz) for 5 years, tested positive for SARS-CoV-2, the causative agent for coronavirus disease 19 (COVID-19). She was asymptomatic at presentation but subsequently developed headache, chest pain, diarrhoea, anorexia and fatigue on day 3 of isolation without cough, fever or shortness of breath. Her CD4 count was 965 cells/mm(3) , the HIV viral load was undetectable (<1,000 cells/mm(3) ) and other laboratory work up was normal. She was successfully managed with hydroxychloroquine and broad spectrum antibiotics, and was discharged after 24 days. This case demonstrates an atypical clinical presentation of COVID - 19 in an HIV infected patient without other co-morbidity. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Baluku, Joseph Baruch","Mwebaza, Shem","Ingabire, Gloria","Nsereko, Chris","Muwanga, Moses"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437000","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26044","keywords":["covid-19","hiv","sars-cov-2","uganda"],"locations":["Uganda","Uganda"],"countries":["Uganda"],"countries_codes":["UGA|Uganda"],"e_drugs":["Tenofovir","Hydroxychloroquine","efavirenz","Lamivudine"],"topics":["Case Report"],"weight":1,"_version_":1667521393570349056,"score":247.73753},{"pmid":32347975,"title":"HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey.","text":["HIV/SARS-CoV-2 co-infected patients in Istanbul, Turkey.","In December 2019, the causative agent of Coronavirus disease 2019 (COVID-19) was identified and named as SARS-CoV-2. Since then it has been spreading and severe form of the illness predominantly occurs in adults with advanced age or underlying comorbidities. The European AIDS Clinical Society states the lack of evidence for a higher COVID-19 infection rate among people living with HIV (PLHIV) and there is a few published literature on the course of COVID-19 co-infection in PLHIV. We described four HIV/SARS-CoV-2 co-infected patients with different characteristics. The impression is that comorbidities is an important factor in mortality in HIV/SARS-CoV-2 co-infected cases. This article is protected by copyright. All rights reserved.","J Med Virol","Altuntas Aydin, Ozlem","Kumbasar Karaosmanoglu, Hayat","Kart Yasar, Kadriye","32347975"],"abstract":["In December 2019, the causative agent of Coronavirus disease 2019 (COVID-19) was identified and named as SARS-CoV-2. Since then it has been spreading and severe form of the illness predominantly occurs in adults with advanced age or underlying comorbidities. The European AIDS Clinical Society states the lack of evidence for a higher COVID-19 infection rate among people living with HIV (PLHIV) and there is a few published literature on the course of COVID-19 co-infection in PLHIV. We described four HIV/SARS-CoV-2 co-infected patients with different characteristics. The impression is that comorbidities is an important factor in mortality in HIV/SARS-CoV-2 co-infected cases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Altuntas Aydin, Ozlem","Kumbasar Karaosmanoglu, Hayat","Kart Yasar, Kadriye"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347975","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25955","keywords":["hiv","sars-cov-2","co-infection"],"locations":["Istanbul","Turkey"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"topics":["Case Report"],"weight":1,"_version_":1666138494930518016,"score":221.51076},{"pmid":32473657,"title":"Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.","text":["Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.","BACKGROUND: Information about incidence, clinical characteristics, and outcomes of HIV-infected individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is scarce. We characterised individuals with COVID-19 among a cohort of HIV-infected adults in Madrid. METHODS: In this observational prospective study, we included all consecutive HIV-infected individuals (aged >/=18 years) who had suspected or confirmed COVID-19 as of April 30, 2020, at the Hospital Universitario Ramon y Cajal (Madrid, Spain). We compared the characteristics of HIV-infected individuals with COVID-19 with a sample of HIV-infected individuals assessed before the COVID-19 pandemic, and described the outcomes of individuals with COVID-19. FINDINGS: 51 HIV-infected individuals were diagnosed with COVID-19 (incidence 1.8%, 95% CI 1.3-2.3). Mean age of patients was 53.3 years (SD 9.5); eight (16%) were women, and 43 (84%) men. 35 (69%) cases of co-infection had laboratory confirmed COVID-19, and 28 (55%) required hospital admission. Age and CD4 cell counts in 51 patients diagnosed with COVID-19 were similar to those in 1288 HIV-infected individuals without; however, 32 (63%) with COVID-19 had at least one comorbidity (mostly hypertension and diabetes) compared with 495 (38%) without COVID-19 (p=0.00059). 37 (73%) patients had received tenofovir before COVID-19 diagnosis compared with 487 (38%) of those without COVID-19 (p=0.0036); 11 (22%) in the COVID-19 group had previous protease inhibitor use (mostly darunavir) compared with 175 (14%; p=0.578). Clinical, analytical, and radiological presentation of COVID-19 in HIV-infected individuals was similar to that described in the general population. Six (12%) individuals were critically ill, two of whom had CD4 counts of less than 200 cells per muL, and two (4%) died. SARS-CoV-2 RT-PCR remained positive after a median of 40 days from symptoms onset in six (32%) individuals, four of whom had severe disease or low nadir CD4 cell counts. INTERPRETATION: HIV-infected individuals should not be considered to be protected from SARS-CoV-2 infection or to have lower risk of severe disease. Generally, they should receive the same treatment approach applied to the general population. FUNDING: None.","Lancet HIV","Vizcarra, Pilar","Perez-Elias, Maria J","Quereda, Carmen","Moreno, Ana","Vivancos, Maria J","Dronda, Fernando","Casado, Jose L","32473657"],"abstract":["BACKGROUND: Information about incidence, clinical characteristics, and outcomes of HIV-infected individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is scarce. We characterised individuals with COVID-19 among a cohort of HIV-infected adults in Madrid. METHODS: In this observational prospective study, we included all consecutive HIV-infected individuals (aged >/=18 years) who had suspected or confirmed COVID-19 as of April 30, 2020, at the Hospital Universitario Ramon y Cajal (Madrid, Spain). We compared the characteristics of HIV-infected individuals with COVID-19 with a sample of HIV-infected individuals assessed before the COVID-19 pandemic, and described the outcomes of individuals with COVID-19. FINDINGS: 51 HIV-infected individuals were diagnosed with COVID-19 (incidence 1.8%, 95% CI 1.3-2.3). Mean age of patients was 53.3 years (SD 9.5); eight (16%) were women, and 43 (84%) men. 35 (69%) cases of co-infection had laboratory confirmed COVID-19, and 28 (55%) required hospital admission. Age and CD4 cell counts in 51 patients diagnosed with COVID-19 were similar to those in 1288 HIV-infected individuals without; however, 32 (63%) with COVID-19 had at least one comorbidity (mostly hypertension and diabetes) compared with 495 (38%) without COVID-19 (p=0.00059). 37 (73%) patients had received tenofovir before COVID-19 diagnosis compared with 487 (38%) of those without COVID-19 (p=0.0036); 11 (22%) in the COVID-19 group had previous protease inhibitor use (mostly darunavir) compared with 175 (14%; p=0.578). Clinical, analytical, and radiological presentation of COVID-19 in HIV-infected individuals was similar to that described in the general population. Six (12%) individuals were critically ill, two of whom had CD4 counts of less than 200 cells per muL, and two (4%) died. SARS-CoV-2 RT-PCR remained positive after a median of 40 days from symptoms onset in six (32%) individuals, four of whom had severe disease or low nadir CD4 cell counts. INTERPRETATION: HIV-infected individuals should not be considered to be protected from SARS-CoV-2 infection or to have lower risk of severe disease. Generally, they should receive the same treatment approach applied to the general population. FUNDING: None."],"journal":"Lancet HIV","authors":["Vizcarra, Pilar","Perez-Elias, Maria J","Quereda, Carmen","Moreno, Ana","Vivancos, Maria J","Dronda, Fernando","Casado, Jose L"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32473657","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/S2352-3018(20)30164-8","locations":["Madrid","Madrid","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932683689984,"score":207.80356},{"pmid":32293709,"title":"Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better.","text":["Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better.","Recently, the first case of HIV and SARS-CoV-2 infection was reported in the literature. With this letter, we proposed a hypothesis that could explain the interaction between HIV infection and the clinical course of SARS-CoV-2 infection. This article is protected by copyright. All rights reserved.","J Med Virol","Mascolo, Silvia","Romanelli, Antonio","Carleo, Maria Aurora","Esposito, Vincenzo","32293709"],"abstract":["Recently, the first case of HIV and SARS-CoV-2 infection was reported in the literature. With this letter, we proposed a hypothesis that could explain the interaction between HIV infection and the clinical course of SARS-CoV-2 infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Mascolo, Silvia","Romanelli, Antonio","Carleo, Maria Aurora","Esposito, Vincenzo"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293709","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25881","keywords":["human immunodeficiency virus","protease inhibitor","sars coronavirus"],"topics":["Case Report"],"weight":1,"_version_":1666138494468096000,"score":197.8107}]}